The DEFA1 antibody targets human alpha-defensin 1 (DEFA1), a small cationic antimicrobial peptide primarily produced by neutrophils. DEFA1 belongs to the α-defensin family, which plays critical roles in innate immunity by directly killing pathogens (e.g., bacteria, viruses, fungi) and modulating immune responses. These peptides are stored in neutrophil granules and released during infection or inflammation. DEFA1. encoded by the *DEFA1* gene located on chromosome 8p23.1. forms pores in microbial membranes, disrupting their integrity. It also acts as a chemoattractant for immune cells and enhances phagocytosis.
DEFA1 antibodies are essential tools in biomedical research and diagnostics. They enable the detection of DEFA1 in tissues or bodily fluids (e.g., saliva, plasma) using techniques like immunohistochemistry (IHC), Western blotting, or ELISA. Such studies help investigate DEFA1’s role in diseases, including infections, inflammatory disorders (e.g., Crohn’s disease), and cancers. Elevated DEFA1 levels are linked to chronic inflammation, while deficiencies may correlate with susceptibility to infections. Commercially available DEFA1 antibodies are typically monoclonal or polyclonal, validated for specificity in human samples. Understanding DEFA1 dynamics via antibody-based assays contributes to therapeutic development, such as designing defensin-inspired antimicrobial agents or biomarkers for disease monitoring.